Literature DB >> 26873136

Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.

Maija P Valta1,2, Hongjuan Zhao1, Matthias Saar1,3, Johanna Tuomela4, Rosalie Nolley1, Johannes Linxweiler3, Jouko Sandholm5, Jaakko Lehtimäki4, Pirkko Härkönen4, Ilsa Coleman6, Peter S Nelson6,7, Eva Corey7, Donna M Peehl8.   

Abstract

LuCaP serially transplantable patient-derived xenografts (PDXs) are valuable preclinical models of locally advanced or metastatic prostate cancer. Using spheroid culture methodology, we recently established cell lines from several LuCaP PDXs. Here, we characterized in depth the features of xenografts derived from LuCaP 136 spheroid cultures and found faithful retention of the phenotype of the original PDX. In vitro culture enabled luciferase transfection into LuCaP 136 spheroids, facilitating in vivo imaging. We showed that LuCaP 136 spheroids formed intratibial, orthotopic, and subcutaneous tumors when re-introduced into mice. Intratibial tumors responded to castration and were highly osteosclerotic. LuCaP 136 is a realistic in vitro-in vivo preclinical model of a subtype of bone metastatic prostate cancer.

Entities:  

Keywords:  Androgen-dependence; Bone metastasis; Osteosclerosis; Prostate cancer

Mesh:

Year:  2016        PMID: 26873136     DOI: 10.1007/s10585-016-9781-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  44 in total

1.  limmaGUI: a graphical user interface for linear modeling of microarray data.

Authors:  James M Wettenhall; Gordon K Smyth
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

Review 2.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

3.  Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.

Authors:  Abdo J Najy; Young Suk Jung; Joshua J Won; M Katie Conley-LaComb; Allen Saliganan; Chong Jai Kim; Elisabeth Heath; Michael L Cher; R Daniel Bonfil; Hyeong-Reh Choi Kim
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

4.  Establishment and serial passage of cell cultures derived from LuCaP xenografts.

Authors:  Sarah R Young; Matthias Saar; Jennifer Santos; Holly M Nguyen; Robert L Vessella; Donna M Peehl
Journal:  Prostate       Date:  2013-06-06       Impact factor: 4.104

5.  Costs of prostate cancer, metastatic to the bone, in the Netherlands.

Authors:  M T Groot; C G G Boeken Kruger; R C M Pelger; C A Uyl-de Groot
Journal:  Eur Urol       Date:  2003-03       Impact factor: 20.096

6.  Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Authors:  Matthias Saar; Hongjuan Zhao; Rosalie Nolley; Sarah R Young; Ilsa Coleman; Peter S Nelson; Robert L Vessella; Donna M Peehl
Journal:  Cancer Lett       Date:  2014-07-03       Impact factor: 8.679

7.  Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

Authors:  Zhi Gang Li; Paul Mathew; Jun Yang; Michael W Starbuck; Amado J Zurita; Jie Liu; Charles Sikes; Asha S Multani; Eleni Efstathiou; Adriana Lopez; Jing Wang; Tina V Fanning; Victor G Prieto; Vikas Kundra; Elba S Vazquez; Patricia Troncoso; Austin K Raymond; Christopher J Logothetis; Sue-Hwa Lin; Sankar Maity; Nora M Navone
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

8.  Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.

Authors:  Kristen D Brubaker; Lisha G Brown; Robert L Vessella; Eva Corey
Journal:  BMC Cancer       Date:  2006-01-17       Impact factor: 4.430

9.  Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers.

Authors:  D J Leeming; M Koizumi; P Qvist; V Barkholt; C Zhang; K Henriksen; I Byrjalsen; M A Karsdal
Journal:  Biomark Cancer       Date:  2011-03-03

10.  Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.

Authors:  Malin Hagberg Thulin; Karin Jennbacken; Jan-Erik Damber; Karin Welén
Journal:  Clin Exp Metastasis       Date:  2013-12-01       Impact factor: 5.150

View more
  5 in total

Review 1.  Heralding a new paradigm in 3D tumor modeling.

Authors:  Eliza L S Fong; Daniel A Harrington; Mary C Farach-Carson; Hanry Yu
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

2.  Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer.

Authors:  Maija Valta; Jani Ylä-Pelto; Yu Lan; Tiina Kähkönen; Pekka Taimen; Peter J Boström; Otto Ettala; Sofia Khan; Niklas Paulin; Laura L Elo; Päivi J Koskinen; Pirkko Härkönen; Johanna Tuomela
Journal:  Transl Androl Urol       Date:  2020-06

3.  Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model.

Authors:  Kerstin Junker; Matthias Saar; Johannes Linxweiler; Turkan Hajili; Christina Körbel; Carolina Berchem; Philip Zeuschner; Andreas Müller; Michael Stöckle; Michael D Menger
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

4.  SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.

Authors:  Meghan A Rice; Vineet Kumar; Dhanir Tailor; Fernando Jose Garcia-Marques; En-Chi Hsu; Shiqin Liu; Abel Bermudez; Vijayalakshmi Kanchustambham; Vishnu Shankar; Zintis Inde; Busola Ruth Alabi; Arvind Muruganantham; Michelle Shen; Mallesh Pandrala; Rosalie Nolley; Merve Aslan; Ali Ghoochani; Arushi Agarwal; Mark Buckup; Manoj Kumar; Catherine C Going; Donna M Peehl; Scott J Dixon; Richard N Zare; James D Brooks; Sharon J Pitteri; Sanjay V Malhotra; Tanya Stoyanova
Journal:  Cell Rep Med       Date:  2022-02-02

5.  Primary Tumor Resection Decelerates Disease Progression in an Orthotopic Mouse Model of Metastatic Prostate Cancer.

Authors:  Johannes Linxweiler; Turkan Hajili; Philip Zeuschner; Michael D Menger; Michael Stöckle; Kerstin Junker; Matthias Saar
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.